Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-05 in Refractory Graves' Disease
NCT07261345Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-05 in Graves' disease, sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 12 months and Remission of Graves' disease at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
RD06-05
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT07261345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261345.